Interferon alfacon-1 clinical trials
How each study uses interferon alfacon-1 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 6 Oct 1997 · Infergen · BLA 103663 (FDA, Purple Book)
- European Union
- 1 Feb 1999 · Infergen · EMEA/H/C/000186 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2005 (2)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2007 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2016 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 3
Sichuan Huiyang Life Science and Technology Corporation (3) · Minneapolis Veterans Affairs Medical Center (1) · Astellas Pharma Inc (1) · Beth Israel Medical Center (1) · Kadmon Corporation, LLC (1) · University Health Network, Toronto (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses interferon alfacon-1 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19CompletedPhase 2Sichuan Huiyang Life Science and Technology CorporationNCT05485584Written as rSIFN-co Nasal Spray
- Study of rSIFN-co for Patients With Advanced Solid TumorsTerminatedPhase 1Sichuan Huiyang Life Science and Technology CorporationNCT02464007Written as rSIFN-co
- A Study of rSIFN-co in Subjects With Advanced Solid TumorsCompletedPhase 1Sichuan Huiyang Life Science and Technology CorporationNCT02387307Written as rSIFN-co
- Hepatitis C Treatment Naive Genotype 1 Consensus Interferon TrialCompletedPhase 3Minneapolis Veterans Affairs Medical CenterNCT00211692Written as consensus interferon (Interferon Alfacon-1) and ribavirin
- Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis CCompletedPhase 3Astellas Pharma IncNCT00239252Written as Interferon alfacon-1
- Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and RibavirinTerminatedPhase 4Kadmon Corporation, LLCNCT00456248Written as Infergen and ribavirin
- Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for InfluenzaStatus unknownPhase 1/2University Health Network, TorontoNCT01227798Written as Interferon alfacon-1
- Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior TherapyCompletedPhase 4Beth Israel Medical CenterNCT00266318Written as Interferon Alfacon-1 and Ribavirin
Codes
What other systems call interferon alfacon-1 · ClinicalTrials.gg INT003304
- MeSH (NLM) C050739interferon alfacon-1Confirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 56588OP40DINTERFERON ALFACON-1Confirmed FDA, NLM, Wikidata
- RxNorm 59744Confirmed FDA, Wikidata
- Wikidata Q15353101interferon alfacon-1Confirmed FDA, NLM, Wikidata
- NCI Thesaurus C1766Interferon Alfacon-1One source FDA
- DrugBank DB00069One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C050739 | interferon alfacon-1 | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 56588OP40D | INTERFERON ALFACON-1 | Confirmed FDA, NLM, Wikidata |
| RxNorm | 59744 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15353101 | interferon alfacon-1 | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1766 | Interferon Alfacon-1 | One source FDA |
| DrugBank | DB00069 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.